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Blood samples from patients with plasma HIV-1 RNA 20 copies/ml for more than 2 years were studied. Significant
decreases in total and integrated HIV-1 DNA were observed during the first 15 months of suppressive therapy before the
concentrations became stable. Clonal analysis of HIV-1 pol demonstrated that the proportions of resistance mutations in
DNA sequences after 2 years were lower than those in baseline DNA and RNA sequences. The changes in the clonal
composition of HIV-1 env populations in three patients with evidence of changes in HIV-1 pol populations indicated a shift
from predominantly R5-like viruses to predominantly X4-like viruses in two patients and the persistence of predominantly
X4-like viruses in the third. Our analyses indicate the reemergence of ancestral sequences from long-lived cells or the
residual production of wild-type virus from anatomic sites with limited access to antiretroviral drugs and the preferentialINTRODUCTION
Treatment of human immunodeficiency virus (HIV-1) in-
fection with highly active antiretroviral therapy (HAART),
including reverse transcriptase and protease inhibitors, has
led to the sustained suppression of virus RNA in the plasma
of many patients. However, replication-competent virus can
routinely be recovered from patients by culturing resting
CD4 T lymphocytes, even from those whose plasma virus
RNA has been undetectable by molecular assays for up to
3 to 4 years (Chun et al., 1997b; Finzi et al., 1997, 1999; Wong
et al., 1997). These observations and molecular techniques
measuring both unintegrated and integrated HIV-1 DNA
(Chun et al., 1995, 1997a, 1998) have led to the suggestion
that the replication-competent integrated provirus in resting
CD4 T lymphocytes could be a source of reactivatable
virus and therefore a major obstacle to eradication of HIV
from infected individuals on HAART. Other observations
also suggest that residual virus replication persists in vivo
despite the lack of detectable HIV-1 RNA in the plasma.
Studies using an ultrasensitive reverse transcriptase–poly-
merase chain reaction (RT–PCR) able to detect cell-free
virion RNA at less than five copies/ml have shown viral RNA
in the plasma of all patients of one cohort of HIV-infected
individuals taking suppressive HAART (Dornadula et al.,
1999). Moreover, several groups have shown low levels of
virus replication in selected patients with low plasma HIV-1RNA by analyzing the cell-associated virus RNA of periph-
eral blood and lymphoı¨d tissue (Cavert et al., 1997; Furtado
et al., 1999; Hockett et al., 1999; Lafeuillade et al., 1998;
Natarajan et al., 1999; Zhang et al., 1999). Finally, HIV-1
cDNA episomes, which are labile products of virus infection
and indicate recent infection, have been detected in a large
percentage of infected individuals on HAART, despite sus-
tained undetectable levels of plasma virus RNA (Sharkey et
al., 2000). However, these data are controversial because
recent studies have suggested that HIV-1 circular DNA
forms may be quite stable (Butler et al., 2002; Pierson et al.,
2002). Extensive genetic studies of env and pol sequences
(Hirsch et al., 2000; Shankarappa et al., 1999) have been
performed in patients with actively replicating virus, but little
is known about the genetic variation of HIV-1 in patients for
whom the control of HIV-1 replication by HAART leads to
sustained undetectable plasma HIV-1 RNA. Significant vari-
ations of HIV-1 sequences from the env gene were found in
some patients, despite their undetectable plasma HIV RNA
(Gunthard et al., 1999; Martinez et al., 1999; Zhang et al.,
1999), but the possible shift in the chemokine receptor used
by HIV-1 strains has not yet been studied, nor has the
evolution of resistant virus populations.
In the present longitudinal study of seven patients
whose plasma HIV-1 RNA had been suppressed for more
than 2 years, we investigated the evolution of genotypic
drug resistance in the protease and reverse transcrip-
tase regions of the pol gene from peripheral blood mono-
nuclear cell (PBMC) DNA. We also examined the evolu-infection of cells expressing CXCR4. © 2002 Elsevier Science (
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CXCR4 for HIV entry (Xiao et al., 1998). Last, we analyzed
the changes in both total and integrated HIV-1 DNA over
a 24-month period.
RESULTS
Patient characteristics
All seven patients showed a rapid decline in plasma
HIV-1 RNA after initiation of treatment. Five patients had
fewer than 200 copies/ml after 3 months of treatment and
all had fewer than 20 copies/ml after 6 months. The
plasma HIV-1 RNA in all the patients remained undetect-
able by the ultrasensitive RT–PCR assay throughout fol-
low-up. There was a gradual increase in the CD4 lym-
phocyte counts of all the patients (P  0.001). The
median increase in the CD4 lymphocyte count was 59
cells/l (range, 2 to 245 cells/l) after 6 months of
treatment, 169 cells/l (range, 43 to 405 cells/l)
after 15 months, and226 cells/l (range,149 to589
cells/l) after 24 months.
Changes in cell-associated total HIV-1 DNA and
integrated proviral DNA
The median cell-associated total number of HIV-1 DNA
copies before active therapy was 3364 copies/106 cells
(range, 65–50,118 copies/106 cells) (Table 1). The concen-
tration of total HIV-1 DNA declined significantly from
3364 copies/106 cells to 324 copies/106 cells (range,
13–1143 copies/106 cells) after 15 months (P  0.001). In
contrast, there was no change in total HIV-1 DNA be-
tween months 15 and 24 (median, 654 copies/106 cells;
range, 26–654 copies/106 cells).
The median number of copies of cell-associated inte-
grated provirus before active therapy was 130 copies/106
cells (range, 26–5976 copies/106 cells). As for total HIV-1
DNA, the concentration of integrated proviral DNA dropped
during the first 15 months (median integrated provirus DNA
at month 15, 45 copies/106 cells; range, 4–130 copies/106
cells; P  0.001), but remained stable thereafter (median
integrated proviral DNA at month 24, 45 copies/106 cells;
range, 4–324 copies/106 cells) (Table 1).
Changes in RT and protease pol regions
Genotype analysis was first performed by sequencing
the first 240 codons of the RT region and the entire
protease region of the pol gene (Table 2). Only virus
species representing more than 20% of the total popula-
tion can be detected using this technique. Mutations
associated with resistance to zidovudine (AZT) were
found in baseline samples from five patients who had
been previously exposed to nucleoside RT inhibitors
(patients 1, 2, 3, 5, and 6). Patients 2 and 5 had similar
baseline RNA and DNA sequences, while the patterns of
mutations in RNA and DNA were different for patients 1,
3, and 6. As expected, no mutations conferring resis-
tance to protease inhibitors were found at baseline,
since all the patients were protease inhibitor-naı¨ve be-
fore active therapy. Comparison of the DNA sequences
from PBMC collected 24 months after suppressive ther-
apy with baseline RNA and DNA sequences revealed no
change in the protease amino acid sequences. No new
mutations associated with resistance to RT inhibitors
were detected, including the M184I/V mutation for the six
patients who were given lamivudine (3TC). Surprisingly,
the amino acid sequences after 24 months of suppres-
sive therapy showed mixtures of wild-type and mutant
viruses (patients 2, 3, and 5) or wild-type virus (patient 6)
in all patients harboring strains with AZT resistance
mutations at baseline, except for one (patient 1).
The changes in HIV-1 populations from patients 2, 3, 5,
and 6 were tracked by measuring the proportions of
mutant and wild-type molecular clones of PCR products
from plasma and PBMC samples before and after 24
months of suppressive therapy. A total of 239 amplicons
were obtained and analyzed phylogenetically by the
neighbor-joining method (Saitou et al., 1987). Sequences
from each patient clustered together, indicating the ab-
sence of sample contamination (data not shown). The
TABLE 1
Patient Characteristics and Effect of Treatment on the Levels of Total HIV-1 DNA and Proviral DNA in PBMC
Patient
No.
Clinical stage
(CDC)
CD4 count at
baseline
(cells/l)
HIV-1 RNA in plasma
(log copies/ml)
Total HIV-1 DNA
(copies/106 cells)
Integrated proviral DNA
(copies/106 cells)
Baseline Months 6–24 Baseline Month 15 Month 24 Baseline Month 15 Month 24
1 B 1 6.5 1.3 7,943 324 654 130 13 65
2 C 5 5.0 1.3 3,364 130 324 324 26 13
3 A 32 3.8 1.3 3,364 324 65 65 130 4
4 C 11 5.6 1.3 654 654 654 65 45 64
5 C 124 5.3 1.3 50,118 1,143 654 5,976 130 324
6 C 2 6.0 1.3 1,143 654 654 229 130 45
10 A 259 3.2 1.3 65 13 26 26 4 4
Median 76 5.1 3,364 324 654 130 45 45
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clonal analysis is summarized in Table 3. Plasma RNA
sequences were more homogeneous than PBMC DNA
sequences. The proportions of mutations conferring re-
sistance to AZT (T215Y/F, M41L, D67N, K70R, L210W, and
K219Q) and to 3TC (M184I/V) in baseline RNA and DNA
sequences revealed more mutations in plasma RNA
(P  0.001), suggesting a greater expression of resis-
tant genotypes in infected cells before active therapy.
There were fewer mutations conferring resistance to AZT
and 3TC in PBMC DNA sequences after 24 months of
suppressive therapy than in the baseline DNA and RNA
sequences (P  0.001); 94–100% of the variants in the
TABLE 2
Drug Resistance Genotype before and after 24 Months of Plasma HIV-1 RNA Suppression
Patient
No. Sampling time Sample
Reverse transcriptase Protease
41 67 70 184 210 215 219 30 46 48 54 82 84 90
M D K M L T K D M G I V I L
1 Baseline Plasma — — E — — — Q — — — — — — —
PBMC — N G — — Y Q — — — — — — —
Month 24 PBMC — N G — — Y Q — — — — — — —
2 Baseline Plasma L N — — W Y — — — — — — — —
PBMC L N — — W Y — — — — — — — —
Month 24 PBMC — — E — — Y/T — — — — — — — —
3 Baseline Plasma — N R — — F E — — — — — — —
PBMC — — — V W Y — — — — — — — —
Month 24 PBMC — — R — — F/T — — — — — — — —
4 Baseline Plasma — — — — — — — — — — — — — —
PBMC — — — — — — — — — — — — — —
Month 24 PBMC — — — — — — — — — — — — — —
5 Baseline Plasma L — — — W Y — — — — — — — —
PBMC L — — — W/L Y — — — — — — — —
Month 24 PBMC L/M — — — — Y/T — — — — — — — —
6 Baseline Plasma L — — — W Y — — — — — — — —
PBMC — — — — W/L Y — — — — — — — —
Month 24 PBMC — — — — — — — — — — — — — —
10 Baseline Plasma — — — — — — —
PBMC — — — — — — —
Month 24 PBMC — — — — — — Q
Note. PBMC, peripheral blood mononuclear cells.
TABLE 3
Evolution of Quasispecies Harboring Mutations Conferring Resistance to Reverse Transcriptase Inhibitors
after 24 Months of Plasma HIV-1 RNA Suppression
Patient
No. Sampling time Sample
Total clones
tested
Mutated clones on RT region (%)
41 67 70 184 210 215 219
M D K M L T K
2 Baseline Plasma 20 100 95 0 0 100 100 0
PBMC 18 83 83 0 0 83 89 0
Month 24 PBMC 18 11 33 0 0 11 50 39
3 Baseline Plasma 20 0 100 100 0 0 95 95
PBMC 22 55 45 36 36 41 59 0
Month 24 PBMC 22 5 45 86 9 5 36 32
5 Baseline Plasma 18 100 0 0 0 94 94 0
PBMC 23 96 0 0 0 48 87 0
Month 24 PBMC 23 57 0 0 0 0 61 0
6 Baseline Plasma 21 95 0 0 0 100 100 0
PBMC 18 17 0 6 0 67 67 0
Month 24 PBMC 16 0 0 13 6 19 31 0
Note. PBMC, peripheral blood mononuclear cells.
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baseline RNA sequences and 59–87% of the baseline
DNA sequences had the major mutation T215Y, while
only 31–61% of the 24-month DNA sequences had this
mutation (P  0.001).
Changes in the V3 env region
Sequences encompassing the V3 region of HIV-1 env
were analyzed from virus in baseline plasma and PBMC
and from virus in PBMC after 15 and 24 months of
suppressive therapy in three patients who had changes
in the RT region (patients 3, 5, and 6). A total of 227
amplicons were obtained and all the PCR products
were analyzed phylogenetically by the neighbor-joining
method (Saitou et al., 1987). Sequences from different
patients did not cluster together, indicating no sample
contamination (Fig. 1). The data for each patient show
virus evolution between baseline RNA and DNA se-
quences and month 15 and month 24 DNA sequences,
although some DNA sequences on therapy were identi-
cal or very close to variants present at baseline (Fig. 1).
The distribution of R5 and X4 variants over the sequential
samples from each patient was estimated from the V3
amino acid sequence. It has been reported that un-
charged residues at position 11 of V3 (mostly serine/
glycine), negatively charged residues at residue 25
(mostly glutamic/aspartic acid), and a net charge of the
V3 loop  5 predicts CCR5 chemokine receptor usage
(Chesebro et al., 1996; Xiao et al., 1998). In contrast,
positively charged residues at positions 11 and 25
(mostly arginine/lysine) and a net positive charge  5
of the V3 loop results in CXCR4 chemokine receptor
usage (Chesebro et al., 1996; Cho et al., 1998; Xiao et al.,
1998). We used the net charge of V3 as the primary
criterion for discriminating between X4-like and R5-like
viruses. Most of the sequences identified as X4-like had
at least one basic amino acid substitution at a relevant
position. As shown in Fig. 2, the baseline RNA se-
quences were extremely homogeneous (only one muta-
tion from the consensus form) and indicated that R5-like
virus was predominant in patients 3 and 6 (100 and 95%,
respectively) and X4-like virus was predominant in pa-
tient 5 (90%). The proportions of X4-like virus in baseline
PBMC were 80% in patient 5, 59% in patient 3, and 37%
in patient 6. Analysis of DNA sequences from PBMC
collected after 15 and 24 months of suppressive therapy
showed that the proportions of X4-like virus increased
over time in patients 3 (68% at month 15, 94% at month
24) and 6 (74% at month 15, 100% at month 24). X4-like
virus remained predominant at month 24 in patient 5
(88%), although the proportions of R5-like and X4-like
clones were similar at month 15 (Fig. 2).
DISCUSSION
This longitudinal study of patients given suppressive
therapy for more than 2 years in which total and integrated
HIV-1 DNA were measured and pol and env quasi-
species characterized demonstrates a shift from a drug-
resistant genotype to a predominantly wild-type geno-
type and a shift from a mainly R5-like virus to a mainly
X4-like virus.
One important issue for assessing virus populations
based on PCR products is the use of a sufficient number
of templates (Liu et al., 1996). The determination of the
distribution of genetic variants that make up the quasi-
species at each time point has not been biased in our
study for several reasons: (i) taking into account baseline
plasma HIV-1 RNA concentrations (3.8–6.0 log copies/
ml), the extraction recovery, and the reverse transcription
step, a large number of target molecules from each
sample were subjected to PCR, (ii) over 300–600 HIV-1
DNA copies/106 cells were used for clonal analysis of all
the samples but one (patient 3, month 24); therefore, at
least 50–100 target molecules were subjected to PCR,
indicating that the average number of distinct clones is
near the number of clones selected, (iii) a similar distri-
bution of variants was obtained on clonal analysis done
on distinct DNA aliquots for selected patients (data not
shown), (iv) sequences obtained by direct sequencing
precisely matched consensus sequences at near all
codons of pol and env fragments (data not shown).
Despite a significant decrease in cell-associated total
HIV DNA of 1 log during the first 15 months of suppres-
sive therapy, the concentration of HIV DNA remained
stable between months 15 and 24 in our patients. The
median half-life of HIV-1 DNA decay during the first 15
months of active therapy was previously estimated at 40
weeks (Izopet et al., 1998a). The change in integrated
HIV DNA over time was similar, with a decrease of 0.5
log after 15 months, but no further decrease thereafter.
The actual stability of total and integrated HIV-1 DNA
after 15 months was confirmed by measuring these pa-
rameters on other cell samples that were available for
three patients (data not shown). These results are in
agreement with those recently reported by Furtado et al.
(1999) showing that the evolution of total and integrated
HIV DNA in subjects on potent antiretroviral therapy was
FIG. 1. Neighbor-joining phylogenetic tree depicting HIV-1 env sequences found in patients 3, 5, and 6. The entire PCR product was used for phylogenetic
analyses. All sequences are shown with LAI (GenBank Accession No. K02013) as the outgroup. RNA sequences derived from baseline plasma are represented
by solid squares. DNA sequences derived from peripheral blood mononuclear cells are indicated by open symbols: open squares (baseline), open circles (month
15), and open stars (month 24). The genetic relatedness of two different sequences in the phylogenetic tree is represented by the horizontal distance that separates
them, with the length of the bar at the bottom denoting a sequence divergence of 0.10. Bootstrap values are expressed as percentages for each relevant branch
and represent the percentage of occurrence of that branch per 1000 bootstrap replicates.
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biphasic, with a substantial decrease during the initial
500 days and a subsequent plateau. Because the tech-
nique used for measuring integrated proviral DNA could
be less efficient than the technique used for measuring
total HIV-1 DNA due to the length of the amplified prod-
uct, it is difficult to estimate accurately the proportions of
both forms. However, the data show that the ratios of
proviral DNA to total HIV-1 DNA at months 15 and 24
were similar to baseline ratios. This point provides indi-
rect evidence of the persistence of unintegrated DNA
suggesting the occurrence of recent infections. Linear
DNA incorporated into the preintegration complex is un-
stable (Zack et al., 1990), while the circular unintegrated
DNA found exclusively in the nucleus is a labile product
of the integration process (Sharkey et al., 2000). But this
latter point needs to be reevaluated (Butler et al., 2002;
Pierson et al., 2002). The stability of integrated DNA after
15 months suggests that the intrinsic decay rate of the
latent reservoir, i.e., resting CD4 T lymphocytes harbor-
ing replication-competent virus, is balanced by an equal
rate of de novo infection regenerating the latent reser-
voir. Ramratnam et al. (2000) showed that the decay of
the latent reservoir of replication-competent HIV was
inversely correlated with the extent of residual virus
replication. This could also partly explain differences in
the reported half-life of replication-competent HIV in the
pool of latently infected, resting CD4 T cells, which
ranges from 44 months (Finzi et al., 1999) to 6 months in
patients with minimal evidence of residual virus replica-
tion (Zhang et al., 1999). Our data are consistent with new
projections of viral decay that take into account the virus
production by cells infected after the initiation of active
therapy (Grossman et al., 1999).
Several studies have used population sequencing of
viral isolates recovered from sensitive cultures to show
that drug resistance mutations do not emerge in patients
with prolonged plasma virus suppression (Finzi et al.,
1997; Gunthard et al., 1998; Wong et al., 1997). This was
also observed in our study by sequencing multiple mo-
lecular clones from the PBMC of several patients ex-
posed to lamivudine, which rapidly selects the M184I/V
mutation, even when there is very little viral replication
(Descamps et al., 2000). However, the month-24 PBMC
from one patient (patient 6) had 1 clone of 16 with the
M184V mutation, suggesting that there was a period
when replication was more rapid in this patient, but
which was not identified because of infrequent sampling.
A similar observation was reported by Martinez et al.
(1999), although their patient had plasma RNA concen-
trations of 20–200 copies/ml. One of our patients given
only a two-drug regimen showed no major mutations
conferring drug resistance after 24 months, suggesting
that a durable antiviral effect can be obtained with a
regimen of modest antiviral potency in some individuals
provided the target of therapy (fewer than 20 copies
RNA/ml) is achieved. Surprisingly, clonal analysis of se-
quential DNA sequences from PBMC of four patients
harboring resistant viral populations before active ther-
apy showed the emergence of wild-type virus at critical
codons for resistance after 24 months. The proportions
of wild-type virus in PBMC increased substantially in all
the patients studied. Because the DNA sequences from
PBMC may reflect earlier steps in viral production and
selection, our results are compatible with the selection of
long-lived cells populations harboring wild-type drug-
sensitive virus (Hermankova et al., 2001). Another possi-
bility is the ongoing production of wild-type virus in
anatomical sites to which antiretroviral drugs have lim-
ited access and/or proximal activation and transmission
involving cells chronically and latently infected with wild-
type virus (Grossman et al., 1998). The precise location of
this viral production remains undefined but many sites,
such as the central nervous system, the genital organs,
and the thymus, are possible candidates (Schrager et al.,
1998). Low drug concentrations at these sites could
generate resistant variants, but their poor fitness could
preclude the emergence of a population of resistant
virus.
We looked for changes in the env sequences in three
patients in which there was evidence of changes in the
pol gene during prolonged plasma HIV RNA suppres-
sion. The chemokine receptor usage of virus populations
in sequential samples was determined by sequencing
multiple molecular clones and analyzing the distribution
of R5- and X4-like viruses. The HIV variants were sepa-
rated according to the net charge of the V3 loop and the
critical amino acid residues at positions 11 and 25 on
either side of the conserved tip of the V3 loop, which are
major determinants of coreceptor usage. Although there
may be discrepancies between genotyping and pheno-
typing for some strains, there seems to be relatively good
agreement between the two methods (Briggs et al., 2000;
Hung et al., 1999; Xiao et al., 1998). Our genetic analysis
showed a shift from mainly R5-like viruses to mainly
X4-like viruses in two patients and the persistence of
predominantly X4-like viruses in the third patient. Chun et
al. (1997b) also detected syncytium-inducing (SI) virus in
resting CD4 T cells induced in vitro in three of nine
patients who had undetectable plasma viremia on
HAART.
The R5 to X4 shift that we observed may be due to the
preferential implication of X4 viruses in the latent reser-
voir. The predominant forms in the PBMC of patient 6
during plasma HIV RNA suppression were identical or
closely related to a minor variant present in baseline
PBMC but not in baseline plasma. Replication-competent
HIV-1 provirus has been detected within naı¨ve CD45RA/
CD62L CD4 T cells (Ostrowski et al., 1999). The pro-
viral loads in memory and naı¨ve CD4 T cell subsets
were similar in the patients who harbored X4 viruses,
while the proviral load in naı¨ve CD4 T cells was very
low in the patients who harbored R5 viruses (Ostrowski
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et al., 1999). It has also been reported that SI variants are
equally distributed between CD45RO cells and naı¨ve
CD45RA cells, in contrast to NSI variants that are
mainly present in memory CD45RO cells (Blaak et al.,
2000). However, a recent study showed that most of the
viruses in latently infected CD4 resting T cells used
CCR5 for entry, although viruses using CXCR4 were also
detected (Pierson et al., 2000). An alternative explanation
of the R5 to X4 shift could be the preferential residual
replication of X4 viruses. The surface densities of CCR5
and CXCR4 on CD4 T cells differs. More CXCR4 is found
on naı¨ve T cells, while CCR5 predominates on memory
and activated T cells (Connor et al., 1997; Feng et al.,
1996; Simmons et al., 1996). Thymocytes express CXCR4
during most stages of maturation, although few thymo-
cytes express CCR5 (Taylor et al., 2001). The preferential
infection of naı¨ve T cells or thymocytes by X4 virus during
prolonged plasma HIV RNA suppression is compatible
with the two distinct phases of immune restoration on
potent antiretroviral therapy: simple redistribution of
memory lymphocytes from lymphoı¨d tissues to the circu-
lation followed by a slower increase in largely naı¨ve
CD4 cells. This probably reflects continued thymic pro-
duction or extrathymic cell division that is no longer
counterbalanced by cell sequestration and destruction
by HIV (Autran et al., 1997; Pakker et al., 1998). Alterna-
tively, the emergence of X4 viruses might be linked to
negative selective forces acting against R5 viruses, such
as chemokines (Trumpfheller et al., 1998), neutralizing
antibodies (Burton et al., 1997), or antiretroviral drugs
(van ’t Wout et al., 1996) in the microenvironment of virus
production.
In summary, we have shown a stability of total and
integrated HIV-1 DNA after 15 months of suppressive
therapy, a shift in the virus populations from drug-resis-
tant variants, and the emergence of X4-like viruses. Our
findings suggest the reemergence of ancestral se-
quences or the residual production of wild-type virus and
the preferential infection of cells expressing CXCR4. Phe-
notypic assays should be useful for better characterizing
HIV-1 from cell reservoirs. The pathogenicity of the emer-
gent X4 viruses in patients on HAART is unclear (Holt-
FIG. 2. Predicted protein sequences of the V3 loop of virus from three patients with 24-month plasma HIV RNA suppression. All letter designations
for amino acids conform to the standard International Union of Pure and Applied Chemistry code. The consensus and clonal sequences are given
for each subject and source. The V3 loops were aligned with reference to the consensus baseline DNA sequence for each patient. Dashes denote
an amino acid that is identical to an amino acid in the consensus baseline DNA sequence. Asterisks denote a gap inserted to maintain alignment.
Replacements are indicated by the appropriate code letter. Residues at positions 11 and 25 have been boxed to highlight the substitutions noted. The
total amino acid charge of the V3 loop was calculated by subtracting the number of negatively charged amino acids (D and E) from the number of
positively charged ones (K and R) using DNAid 1.8 software (Frederic Dardel, Palaiseau, France).
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kamp et al., 2000). Further longitudinal studies are
needed to determine whether the emergence of X4 virus
influences the T cell turnover or simply reflects a change
in cell dynamics in patients on potent antiretroviral ther-
apy.
MATERIALS AND METHODS
Patients
Subjects were selected from a well-characterized co-
hort of HIV-1-infected patients treated at the Department
of Infectious Diseases of Toulouse University Hospital
(Toulouse, France) (Izopet et al., 1998a). Informed con-
sent was obtained from all the subjects. Each had had
continued suppression of plasma HIV RNA for more than
2 years, as assessed at 3-month intervals by the ultra-
sensitive Amplicor HIV-1 Monitor RT–PCR assay (Roche
Diagnostics, Meylan, France). The subjects were four
men and three women, with a mean age of 35 years, who
were classified as U.S. Centers for Disease Control and
Prevention (CDC) class A (n  2), B (n  1), or C (n 
4) (Table 1). The median baseline CD4 count was 76
cells/l (range, 1–259 cells/l) and the median baseline
plasma RNA was 5.1 copies/ml (range, 3.2–6.5 copies/
ml). Six patients (patients 1–6) were placed on a first
triple-drug regimen consisting of zidovudine (AZT) 
lamivudine (3TC)  indinavir (IDV) after multiple failures
of nucleoside reverse transcriptase inhibitor-based ther-
apies. The remaining patient (patient 10) was given a first
line AZT  zalcitabine (ddC) regimen.
CD4 T lymphocyte count
Peripheral blood CD4 T lymphocytes were counted
by flow cytometry (Epics Profile; Coulter, Hialeah, Flor-
ida) using commercially available monoclonal antibodies
(Beckton–Dickinson, Mountain View, California).
Plasma HIV-1 RNA
The HIV-1 RNA in the plasma was measured using the
ultrasensitive Amplicor HIV-1 Monitor RT–PCR assay
(Roche Diagnostics) according to the manufacturer’s in-
FIG. 2—Continued
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structions. The lower limit of detection of the assay was
20 copies/ml.
Cell-associated total and integrated HIV-1 DNA
Total and integrated HIV-1 DNA were measured by
end point dilution PCR. Serial fivefold dilutions were
prepared from a lysate of 1  106 PBMC and duplicate
aliquots of each dilution were amplified and then de-
tected. Total HIV-1 DNA was measured using gag prim-
ers (Amplicor HIV-1, Roche Diagnostics) as previously
described (Izopet et al., 1998b). Integrated HIV-1 DNA
was measured by an Alu–PCR method and nested prim-
ers (Chun et al., 1997a). The external primers were Alu–
long terminal repeats (LTR) 5 from conserved se-
quences of human Alu and Alu–LTR 3 from conserved
HIV-1 LTR sequences. The internal primers, NI-2 5 and
NI-2 3, allowed amplification of a portion of the LTR
region of HIV-1 DNA. The copy numbers of total and
integrated DNA were determined from the limiting dilu-
tion PCR data by the method of maximum likelihood
(Myers et al., 1994).
Sequencing the HIV-1 pol and env genes
Nucleic acid isolation, cDNA synthesis, and PCR am-
plification of DNA and cDNA were performed as previ-
ously described (Izopet et al., 1998a; Pasquier et al.,
1998). All the appropriate measures to prevent contami-
nation, such the aliquoting of all reagents and the phys-
ical separation of sample processing and post-PCR han-
dling steps, were strictly applied (Kwok et al., 1989). The
first 240 codons of the reverse transcriptase region was
amplified using RT1 (sense primer, 5-GGAAACCAAAA-
ATGATAGGGGGAATTGGAGG-3; nucleotides (nt) 1959 to
1989 of the HIVLAI genome) and RT2 (antisense primer,
5-TCTACTTGTCCATGCATGGCTTC-3; nt 3975–3953) as
outer primers and RT3 (sense primer 5-ATTTTCCCATT-
AGTCCTATT-3; nt 2127–2146) and RT4 (antisense primer,
5-ATGTCATTGACAGTCCAGCT-3; nt 2901–2882) as in-
ner primers. The entire protease region was amplified
using PR1 (sense primer, 5-AGAGCTTCAGGTTTGGGG-
3; nt 1753–1770) and PR2 (antisense primer, 5-GC-
CATCCATTCCTGGCTT-3; nt 2185–2168) as outer primers
and PR3 (sense primer, 5-GAAGCAGGAGCCGATAG-
ACA-3; nt 1794–1812) and PR4 (antisense primer, 5-
ACTGGTACAGTTTCAATA-3; nt 2160–2143) as inner prim-
ers. A region of 667 nucleotides encoding the gp120 V3
loop was amplified using E1 (sense primer, 5-TTAG-
GCATCTCCTATGGCAGGAAGCGG-3; 5956–5985 of the
HIVHXB2 genome) and E2 (antisense primer, 5-AGTGCT-
TCCTGCTGCTCCCAAGAACCCAAG-3; 7810–7781) as
outer primers and E3 (sense primer, 5-CTGTTAAATG-
GCAGTCTAGC-3; 7001–7020) and E4 (antisense primer,
5-CACTTCTCCAATTGTCCCTCA-3; 7661–7647) as inner
primers. The limit of detection for the nested primer pairs
that flank the reverse transcriptase, protease, and env
regions was five copies of template DNA. The amplifica-
tion products were sequenced in the sense and anti-
sense directions by the dideoxy chain-termination
method (ABI PRISM Ready Reaction AmpliTaq Fs, Dye
Deoxy Terminators, Applied Biosystems, Paris, France)
FIG. 2—Continued
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on an ABI 377 automated DNA sequencer (Applied Bio-
systems).
Plasmid cloning
The PCR products from several samples amplified
with inner primers were purified with QIAamp columns
(Qiagen, Courtaboeuf, France) and cloned with the PCRII
TA cloning kit (Invitrogen BV, Leek, The Netherlands).
Recombinant plasmids were used to transform compe-
tent Escherichia coli cells according to the manufactur-
er’s protocol, and transformants were grown on ampicil-
lin plates; 17–23 clones from PCR products of each
region were selected. Plasmid DNAs containing env or
pol inserts were prepared and sequenced on both
strands with dye-labeled universal and reverse M13
primers (ABI PRISM, Dye Primer Cycle Sequencing
Ready Reaction Kit, Applied Biosystems) on an ABI 377
automated DNA sequencer (Applied Biosystems). The
rate of misincorporation generated by the above protocol
was evaluated by sequencing 20 clones from two differ-
ent PCR experiments on LAV-8E5 cells containing one
copy of HIV-1 provirus per cell. The misincorporation rate
was 0.047% (1/2,086), corresponding to three point mu-
tations.
Analysis of sequence data
Electropherogram data were analyzed using the Se-
quence Navigator program (Applied Biosystems). Multi-
ple alignments were done with CLUSTALW version 1.7
(Thompson et al., 1996). Sequences from the entire PCR
products were compared to each other and to control
sequences by phylogenetic analysis and distance map-
ping (Saitou et al., 1987) to exclude any possibility of
sample contamination or mix-up. Phylogenetic distances
of env sequences from three patients (patients 3, 5, and
6) were calculated with the two-parameter Kimura algo-
rithm applying a transition/transversion ratio of 2.0 (DNA-
DIST from PHYLIP). Dendograms were created by the
neighbor-joining method with the CLUSTALW program
and tree diagrams were plotted with the TREEVIEW pro-
gram. Bootstrap analysis consisting of 1000 replicates
was performed with the CLUSTALW program. The fre-
quency with which the node occurred is indicated at
each relevant branch point. Bootstrapping was per-
formed with the CLUSTALW program. Charges were cal-
culated from the peptide sequence of the V3 loop region
by subtracting the number of negatively charged amino
acids (D and E) from the number of positively charged
amino acids (K and R) using DNAid 1.8 software (Frederic
Dardel, Palaiseau, France).
Nucleotide sequence Accession numbers
All the sequences reported here have been submitted
to GenBank and were given Accession Nos. AJ225914,
AJ225916, AJ225917, AJ225921, AJ225925, AJ225928-
AJ225931, AJ225945, AJ225946, AJ225948, AJ225951,
AJ225952, AY029809–AY030047, and AF368527–AF368753.
Statistical analysis
Quantitative variables were analyzed by the Wilcoxon
test and by the Friedman test for repeated measures.
Qualitative variables were analyzed by 2 test or Fisher’s
exact probability test. A value of P  0.05 was consid-
ered statistically significant.
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